0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Familial Amyloid Polyneuropathy Therapeutic Market Research Report 2022
Published Date: August 2022
|
Report Code: QYRE-Auto-3V12140
Home | Market Reports | Health| Aging & Geriatrics
Global Familial Amyloid Polyneuropathy Therapeutic Market Research Report 2022
BUY CHAPTERS

Global Familial Amyloid Polyneuropathy Therapeutic Market Research Report 2022

Code: QYRE-Auto-3V12140
Report
August 2022
88 Pages
QYResearch
Region: Global
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
Familial Amyloid Polyneuropathy (FAP) is a progressive, disabling and life-threatening polyneuropathy affecting the peripheral and autonomic nervous system. FAP is an autosomal transmission disorder which is usually due to a point mutation of the transthyretin (TTR) gene.The treatment of familial amyloid polyneuropathies (FAP) is complex and requires a neurological and cardiological multidisciplinary coverage. It includes specific treatments to control the progression of the systemic amyloidogenesis, the symptomatic treatment of the peripheral and autonomic neuropathy (digestive, urinary, sexual, postural hypotension) and the treatment of organs severely involved by amyloidosis (heart, eyes, kidneys).
Highlights

The global Familial Amyloid Polyneuropathy Therapeutic market is projected to reach US$ million by 2028 from an estimated US$ million in 2022, at a CAGR of % during 2023 and 2028.

North American market for Familial Amyloid Polyneuropathy Therapeutic is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.

Asia-Pacific market for Familial Amyloid Polyneuropathy Therapeutic is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2022 through 2028.

The global market for Familial Amyloid Polyneuropathy Therapeutic in Hospital Pharmacies is estimated to increase from $ million in 2022 to $ million by 2028, at a CAGR of % during the forecast period of 2022 through 2028.

The major global companies of Familial Amyloid Polyneuropathy Therapeutic include Pfizer Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Corino Therapeutics Inc., Proclara Biosciences and Arcturus Therapeutics Inc, etc. In 2021, the world's top three vendors accounted for approximately % of the revenue.

Considering the economic change due to COVID-19, Inotersen, which accounted for % of the global market of Familial Amyloid Polyneuropathy Therapeutic in 2021, is expected to reach US$ million by 2028, growing at a revised CAGR of % from 2022 to 2028.

Report Scope
This report aims to provide a comprehensive presentation of the global market for Familial Amyloid Polyneuropathy Therapeutic, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Familial Amyloid Polyneuropathy Therapeutic.
The Familial Amyloid Polyneuropathy Therapeutic market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Familial Amyloid Polyneuropathy Therapeutic market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Familial Amyloid Polyneuropathy Therapeutic companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue by companies for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
Pfizer Inc.
Alnylam Pharmaceuticals Inc.
Ionis Pharmaceuticals Inc.
Corino Therapeutics Inc.
Proclara Biosciences
Arcturus Therapeutics Inc
Product Type Insights
Global markets are presented by Familial Amyloid Polyneuropathy Therapeutic type, along with growth forecasts through 2028. Estimates on revenue are based on the price in the supply chain at which the Familial Amyloid Polyneuropathy Therapeutic are procured by the companies.
This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows revenue data by type, and during the historical period (2017-2022) and forecast period (2023-2028).
Familial Amyloid Polyneuropathy Therapeutic segment by Drug Type
Inotersen
Tafamidis
Patisiran
Others
Application Insights
This report has provided the market size (revenue data) by application, during the historical period (2017-2022) and forecast period (2023-2028).
This report also outlines the market trends of each segment and consumer behaviors impacting the Familial Amyloid Polyneuropathy Therapeutic market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Familial Amyloid Polyneuropathy Therapeutic market.

Familial Amyloid Polyneuropathy Therapeutic Segment by Application

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
Regional Outlook
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue data of each region and country for the period 2017-2028.
The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2021 because of the base year, with estimates for 2022 and forecast revenue for 2028.
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Familial Amyloid Polyneuropathy Therapeutic market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Reasons to Buy This Report
This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Familial Amyloid Polyneuropathy Therapeutic market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
This report will help stakeholders to understand the global industry status and trends of Familial Amyloid Polyneuropathy Therapeutic and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
This report stays updated with novel technology integration, features, and the latest developments in the market
This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Familial Amyloid Polyneuropathy Therapeutic industry.
This report helps stakeholders to gain insights into which regions to target globally
This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Familial Amyloid Polyneuropathy Therapeutic.

This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Familial Amyloid Polyneuropathy Therapeutic companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Drug Type
1.2.1 Global Familial Amyloid Polyneuropathy Therapeutic Market Size Growth Rate by Drug Type: 2017 VS 2021 VS 2028
1.2.2 Inotersen
1.2.3 Tafamidis
1.2.4 Patisiran
1.2.5 Others
1.3 Market by Application
1.3.1 Global Familial Amyloid Polyneuropathy Therapeutic Market Share by Application: 2017 VS 2021 VS 2028
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Familial Amyloid Polyneuropathy Therapeutic Market Perspective (2017-2028)
2.2 Familial Amyloid Polyneuropathy Therapeutic Growth Trends by Region
2.2.1 Familial Amyloid Polyneuropathy Therapeutic Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Familial Amyloid Polyneuropathy Therapeutic Historic Market Size by Region (2017-2022)
2.2.3 Familial Amyloid Polyneuropathy Therapeutic Forecasted Market Size by Region (2023-2028)
2.3 Familial Amyloid Polyneuropathy Therapeutic Market Dynamics
2.3.1 Familial Amyloid Polyneuropathy Therapeutic Industry Trends
2.3.2 Familial Amyloid Polyneuropathy Therapeutic Market Drivers
2.3.3 Familial Amyloid Polyneuropathy Therapeutic Market Challenges
2.3.4 Familial Amyloid Polyneuropathy Therapeutic Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Familial Amyloid Polyneuropathy Therapeutic Players by Revenue
3.1.1 Global Top Familial Amyloid Polyneuropathy Therapeutic Players by Revenue (2017-2022)
3.1.2 Global Familial Amyloid Polyneuropathy Therapeutic Revenue Market Share by Players (2017-2022)
3.2 Global Familial Amyloid Polyneuropathy Therapeutic Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Familial Amyloid Polyneuropathy Therapeutic Revenue
3.4 Global Familial Amyloid Polyneuropathy Therapeutic Market Concentration Ratio
3.4.1 Global Familial Amyloid Polyneuropathy Therapeutic Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Familial Amyloid Polyneuropathy Therapeutic Revenue in 2021
3.5 Familial Amyloid Polyneuropathy Therapeutic Key Players Head office and Area Served
3.6 Key Players Familial Amyloid Polyneuropathy Therapeutic Product Solution and Service
3.7 Date of Enter into Familial Amyloid Polyneuropathy Therapeutic Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Familial Amyloid Polyneuropathy Therapeutic Breakdown Data by Drug Type
4.1 Global Familial Amyloid Polyneuropathy Therapeutic Historic Market Size by Drug Type (2017-2022)
4.2 Global Familial Amyloid Polyneuropathy Therapeutic Forecasted Market Size by Drug Type (2023-2028)
5 Familial Amyloid Polyneuropathy Therapeutic Breakdown Data by Application
5.1 Global Familial Amyloid Polyneuropathy Therapeutic Historic Market Size by Application (2017-2022)
5.2 Global Familial Amyloid Polyneuropathy Therapeutic Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Familial Amyloid Polyneuropathy Therapeutic Market Size (2017-2028)
6.2 North America Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2017-2022)
6.3 North America Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2023-2028)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Familial Amyloid Polyneuropathy Therapeutic Market Size (2017-2028)
7.2 Europe Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2017-2022)
7.3 Europe Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Familial Amyloid Polyneuropathy Therapeutic Market Size (2017-2028)
8.2 Asia-Pacific Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2017-2022)
8.3 Asia-Pacific Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Familial Amyloid Polyneuropathy Therapeutic Market Size (2017-2028)
9.2 Latin America Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2017-2022)
9.3 Latin America Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Market Size (2017-2028)
10.2 Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2017-2022)
10.3 Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Pfizer Inc.
11.1.1 Pfizer Inc. Company Detail
11.1.2 Pfizer Inc. Business Overview
11.1.3 Pfizer Inc. Familial Amyloid Polyneuropathy Therapeutic Introduction
11.1.4 Pfizer Inc. Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2017-2022)
11.1.5 Pfizer Inc. Recent Development
11.2 Alnylam Pharmaceuticals Inc.
11.2.1 Alnylam Pharmaceuticals Inc. Company Detail
11.2.2 Alnylam Pharmaceuticals Inc. Business Overview
11.2.3 Alnylam Pharmaceuticals Inc. Familial Amyloid Polyneuropathy Therapeutic Introduction
11.2.4 Alnylam Pharmaceuticals Inc. Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2017-2022)
11.2.5 Alnylam Pharmaceuticals Inc. Recent Development
11.3 Ionis Pharmaceuticals Inc.
11.3.1 Ionis Pharmaceuticals Inc. Company Detail
11.3.2 Ionis Pharmaceuticals Inc. Business Overview
11.3.3 Ionis Pharmaceuticals Inc. Familial Amyloid Polyneuropathy Therapeutic Introduction
11.3.4 Ionis Pharmaceuticals Inc. Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2017-2022)
11.3.5 Ionis Pharmaceuticals Inc. Recent Development
11.4 Corino Therapeutics Inc.
11.4.1 Corino Therapeutics Inc. Company Detail
11.4.2 Corino Therapeutics Inc. Business Overview
11.4.3 Corino Therapeutics Inc. Familial Amyloid Polyneuropathy Therapeutic Introduction
11.4.4 Corino Therapeutics Inc. Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2017-2022)
11.4.5 Corino Therapeutics Inc. Recent Development
11.5 Proclara Biosciences
11.5.1 Proclara Biosciences Company Detail
11.5.2 Proclara Biosciences Business Overview
11.5.3 Proclara Biosciences Familial Amyloid Polyneuropathy Therapeutic Introduction
11.5.4 Proclara Biosciences Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2017-2022)
11.5.5 Proclara Biosciences Recent Development
11.6 Arcturus Therapeutics Inc
11.6.1 Arcturus Therapeutics Inc Company Detail
11.6.2 Arcturus Therapeutics Inc Business Overview
11.6.3 Arcturus Therapeutics Inc Familial Amyloid Polyneuropathy Therapeutic Introduction
11.6.4 Arcturus Therapeutics Inc Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2017-2022)
11.6.5 Arcturus Therapeutics Inc Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
    Table 1. Global Familial Amyloid Polyneuropathy Therapeutic Market Size Growth Rate by Drug Type (US$ Million): 2017 VS 2021 VS 2028
    Table 2. Key Players of Inotersen
    Table 3. Key Players of Tafamidis
    Table 4. Key Players of Patisiran
    Table 5. Key Players of Others
    Table 6. Global Familial Amyloid Polyneuropathy Therapeutic Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028
    Table 7. Global Familial Amyloid Polyneuropathy Therapeutic Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
    Table 8. Global Familial Amyloid Polyneuropathy Therapeutic Market Size by Region (2017-2022) & (US$ Million)
    Table 9. Global Familial Amyloid Polyneuropathy Therapeutic Market Share by Region (2017-2022)
    Table 10. Global Familial Amyloid Polyneuropathy Therapeutic Forecasted Market Size by Region (2023-2028) & (US$ Million)
    Table 11. Global Familial Amyloid Polyneuropathy Therapeutic Market Share by Region (2023-2028)
    Table 12. Familial Amyloid Polyneuropathy Therapeutic Market Trends
    Table 13. Familial Amyloid Polyneuropathy Therapeutic Market Drivers
    Table 14. Familial Amyloid Polyneuropathy Therapeutic Market Challenges
    Table 15. Familial Amyloid Polyneuropathy Therapeutic Market Restraints
    Table 16. Global Familial Amyloid Polyneuropathy Therapeutic Revenue by Players (2017-2022) & (US$ Million)
    Table 17. Global Familial Amyloid Polyneuropathy Therapeutic Market Share by Players (2017-2022)
    Table 18. Global Top Familial Amyloid Polyneuropathy Therapeutic Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Familial Amyloid Polyneuropathy Therapeutic as of 2021)
    Table 19. Ranking of Global Top Familial Amyloid Polyneuropathy Therapeutic Companies by Revenue (US$ Million) in 2021
    Table 20. Global 5 Largest Players Market Share by Familial Amyloid Polyneuropathy Therapeutic Revenue (CR5 and HHI) & (2017-2022)
    Table 21. Key Players Headquarters and Area Served
    Table 22. Key Players Familial Amyloid Polyneuropathy Therapeutic Product Solution and Service
    Table 23. Date of Enter into Familial Amyloid Polyneuropathy Therapeutic Market
    Table 24. Mergers & Acquisitions, Expansion Plans
    Table 25. Global Familial Amyloid Polyneuropathy Therapeutic Market Size by Drug Type (2017-2022) & (US$ Million)
    Table 26. Global Familial Amyloid Polyneuropathy Therapeutic Revenue Market Share by Drug Type (2017-2022)
    Table 27. Global Familial Amyloid Polyneuropathy Therapeutic Forecasted Market Size by Drug Type (2023-2028) & (US$ Million)
    Table 28. Global Familial Amyloid Polyneuropathy Therapeutic Revenue Market Share by Drug Type (2023-2028)
    Table 29. Global Familial Amyloid Polyneuropathy Therapeutic Market Size by Application (2017-2022) & (US$ Million)
    Table 30. Global Familial Amyloid Polyneuropathy Therapeutic Revenue Market Share by Application (2017-2022)
    Table 31. Global Familial Amyloid Polyneuropathy Therapeutic Forecasted Market Size by Application (2023-2028) & (US$ Million)
    Table 32. Global Familial Amyloid Polyneuropathy Therapeutic Revenue Market Share by Application (2023-2028)
    Table 33. North America Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2017-2022) & (US$ Million)
    Table 34. North America Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2023-2028) & (US$ Million)
    Table 35. Europe Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2017-2022) & (US$ Million)
    Table 36. Europe Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2023-2028) & (US$ Million)
    Table 37. Asia-Pacific Familial Amyloid Polyneuropathy Therapeutic Market Size by Region (2017-2022) & (US$ Million)
    Table 38. Asia-Pacific Familial Amyloid Polyneuropathy Therapeutic Market Size by Region (2023-2028) & (US$ Million)
    Table 39. Latin America Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2017-2022) & (US$ Million)
    Table 40. Latin America Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2023-2028) & (US$ Million)
    Table 41. Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2017-2022) & (US$ Million)
    Table 42. Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2023-2028) & (US$ Million)
    Table 43. Pfizer Inc. Company Detail
    Table 44. Pfizer Inc. Business Overview
    Table 45. Pfizer Inc. Familial Amyloid Polyneuropathy Therapeutic Product
    Table 46. Pfizer Inc. Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2017-2022) & (US$ Million)
    Table 47. Pfizer Inc. Recent Development
    Table 48. Alnylam Pharmaceuticals Inc. Company Detail
    Table 49. Alnylam Pharmaceuticals Inc. Business Overview
    Table 50. Alnylam Pharmaceuticals Inc. Familial Amyloid Polyneuropathy Therapeutic Product
    Table 51. Alnylam Pharmaceuticals Inc. Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2017-2022) & (US$ Million)
    Table 52. Alnylam Pharmaceuticals Inc. Recent Development
    Table 53. Ionis Pharmaceuticals Inc. Company Detail
    Table 54. Ionis Pharmaceuticals Inc. Business Overview
    Table 55. Ionis Pharmaceuticals Inc. Familial Amyloid Polyneuropathy Therapeutic Product
    Table 56. Ionis Pharmaceuticals Inc. Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2017-2022) & (US$ Million)
    Table 57. Ionis Pharmaceuticals Inc. Recent Development
    Table 58. Corino Therapeutics Inc. Company Detail
    Table 59. Corino Therapeutics Inc. Business Overview
    Table 60. Corino Therapeutics Inc. Familial Amyloid Polyneuropathy Therapeutic Product
    Table 61. Corino Therapeutics Inc. Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2017-2022) & (US$ Million)
    Table 62. Corino Therapeutics Inc. Recent Development
    Table 63. Proclara Biosciences Company Detail
    Table 64. Proclara Biosciences Business Overview
    Table 65. Proclara Biosciences Familial Amyloid Polyneuropathy Therapeutic Product
    Table 66. Proclara Biosciences Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2017-2022) & (US$ Million)
    Table 67. Proclara Biosciences Recent Development
    Table 68. Arcturus Therapeutics Inc Company Detail
    Table 69. Arcturus Therapeutics Inc Business Overview
    Table 70. Arcturus Therapeutics Inc Familial Amyloid Polyneuropathy Therapeutic Product
    Table 71. Arcturus Therapeutics Inc Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2017-2022) & (US$ Million)
    Table 72. Arcturus Therapeutics Inc Recent Development
    Table 73. Research Programs/Design for This Report
    Table 74. Key Data Information from Secondary Sources
    Table 75. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Familial Amyloid Polyneuropathy Therapeutic Market Share by Drug Type: 2021 VS 2028
    Figure 2. Inotersen Features
    Figure 3. Tafamidis Features
    Figure 4. Patisiran Features
    Figure 5. Others Features
    Figure 6. Global Familial Amyloid Polyneuropathy Therapeutic Market Share by Application in 2021 & 2028
    Figure 7. Hospital Pharmacies Case Studies
    Figure 8. Retail Pharmacies Case Studies
    Figure 9. Online Pharmacies Case Studies
    Figure 10. Others Case Studies
    Figure 11. Familial Amyloid Polyneuropathy Therapeutic Report Years Considered
    Figure 12. Global Familial Amyloid Polyneuropathy Therapeutic Market Size (US$ Million), Year-over-Year: 2017-2028
    Figure 13. Global Familial Amyloid Polyneuropathy Therapeutic Market Size, (US$ Million), 2017 VS 2021 VS 2028
    Figure 14. Global Familial Amyloid Polyneuropathy Therapeutic Market Share by Region: 2021 VS 2028
    Figure 15. Global Familial Amyloid Polyneuropathy Therapeutic Market Share by Players in 2021
    Figure 16. Global Top Familial Amyloid Polyneuropathy Therapeutic Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Familial Amyloid Polyneuropathy Therapeutic as of 2021)
    Figure 17. The Top 10 and 5 Players Market Share by Familial Amyloid Polyneuropathy Therapeutic Revenue in 2021
    Figure 18. North America Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 19. North America Familial Amyloid Polyneuropathy Therapeutic Market Share by Country (2017-2028)
    Figure 20. United States Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 21. Canada Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 22. Europe Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 23. Europe Familial Amyloid Polyneuropathy Therapeutic Market Share by Country (2017-2028)
    Figure 24. Germany Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 25. France Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 26. U.K. Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 27. Italy Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 28. Russia Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 29. Nordic Countries Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 30. Asia-Pacific Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 31. Asia-Pacific Familial Amyloid Polyneuropathy Therapeutic Market Share by Region (2017-2028)
    Figure 32. China Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 33. Japan Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 34. South Korea Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 35. Southeast Asia Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 36. India Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 37. Australia Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 38. Latin America Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 39. Latin America Familial Amyloid Polyneuropathy Therapeutic Market Share by Country (2017-2028)
    Figure 40. Mexico Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 41. Brazil Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 42. Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 43. Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Market Share by Country (2017-2028)
    Figure 44. Turkey Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 45. Saudi Arabia Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 46. Pfizer Inc. Revenue Growth Rate in Familial Amyloid Polyneuropathy Therapeutic Business (2017-2022)
    Figure 47. Alnylam Pharmaceuticals Inc. Revenue Growth Rate in Familial Amyloid Polyneuropathy Therapeutic Business (2017-2022)
    Figure 48. Ionis Pharmaceuticals Inc. Revenue Growth Rate in Familial Amyloid Polyneuropathy Therapeutic Business (2017-2022)
    Figure 49. Corino Therapeutics Inc. Revenue Growth Rate in Familial Amyloid Polyneuropathy Therapeutic Business (2017-2022)
    Figure 50. Proclara Biosciences Revenue Growth Rate in Familial Amyloid Polyneuropathy Therapeutic Business (2017-2022)
    Figure 51. Arcturus Therapeutics Inc Revenue Growth Rate in Familial Amyloid Polyneuropathy Therapeutic Business (2017-2022)
    Figure 52. Bottom-up and Top-down Approaches for This Report
    Figure 53. Data Triangulation
    Figure 54. Key Executives Interviewed
SELECT A FORMAT
Added to Cart

Electronic (PDF)
$2900
This license allows only one user to access the PDF.

Electronic (PDF)
$4350
This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Electronic (PDF)
$5800
This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (10% Discount)
OUR CUSTOMER
Nano String
SIMILAR REPORTS